Abstract
Acute myeloid leukemia (AML) represents a heterogeneous group of malignant hematopoietic stem cell disorders. Strategies to describe the complex leukemogenic events in AML include delineation of the mutational landscape, characterization of cellular pathways associated with the leukemic phenotype, and assessment of the role of the immune system and microenvironment in initiating and maintaining the neoplastic clone. An abundance of new potentially drugable targets coupled with technological breakthroughs may enable us to treat patients in a personalized approach based on specific genetic mutations and on leukemia-driving biological pathways. Most of these new "targeted" compounds are still in early clinical development. Moreover, current data suggest that even with these novel agents, resistance is still a major issue and that combination therapy may be needed to overcome this problem. These advancements hold hope for improving the grim outcome that most patients with AML face with current therapeutic approaches.
| Original language | English |
|---|---|
| Title of host publication | Targeted Therapy in Translational Cancer Research |
| Publisher | Wiley-Blackwell |
| Pages | 89-100 |
| Number of pages | 12 |
| ISBN (Electronic) | 9781118468678 |
| ISBN (Print) | 9781118468579 |
| DOIs | |
| State | Published - 30 Oct 2015 |
| Externally published | Yes |
Keywords
- Acute myeloid leukemia
- Apoptosis
- Cancer metabolism
- Chimeric T-cell receptors
- Immune evasion
- Leukemia microenvironment
- Monoclonal antibodies
- Mutations
- Targeted therapy
- Tyrosine kinase inhibitors
